Business
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA. EB613 is being developed as the first once-daily oral anabolic (bone forming
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio Ltd.","displaySize":"","headline":null,"caption":"Entera Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XGS._Ivm6nmvEHmx.FpICw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65","width":164,"height":92}},"lazy":false},{"type":"text","content":"JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was selected for oral presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting, taking place September 5-8 in Seattle, Washington, USA.","length":423,"tagName":"p"},{"type":"text","content":"EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture. The Phase 2 study randomized 161 postmenopausal women with low bone mass or osteoporosis to placebo or four EB613 doses levels for 6 months. Previously published changes in biochemical markers of bone turnover suggest a dual effect to stimulate formation and inhibit resorption. In addition, EB613 significantly increased BMD at each measured skeletal site as compared with baseline and placebo. To explore the dual actions of EB613 further, 3D-DXA analysis was performed using 3-D Shaper software to assess the effects on trabecular and cortical bone.","length":773,"tagName":"p"},{"type":"text","content":"It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and approximately 1 in 5 adults will die within the year following a hip fracture. Postmenopausal osteoporosis afflicts more women than cancer and cardiovascular disease and is a serious health concern for an estimated 200 million women globally.","length":365,"tagName":"p"},{"type":"text","content":"“We are grateful for the honor of being selected for an oral presentation at ASBMR. The 3D-Shaper analysis of our BMD fin...